Cargando…
Thresholds for post-rebound SHIV control after CCR5 gene-edited autologous hematopoietic cell transplantation
Autologous, CCR5 gene-edited hematopoietic stem and progenitor cell (HSPC) transplantation is a promising strategy for achieving HIV remission. However, only a fraction of HSPCs can be edited ex vivo to provide protection against infection. To project the thresholds of CCR5-edition necessary for HIV...
Autores principales: | Cardozo-Ojeda, E Fabian, Duke, Elizabeth R, Peterson, Christopher W, Reeves, Daniel B, Mayer, Bryan T, Kiem, Hans-Peter, Schiffer, Joshua T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803377/ https://www.ncbi.nlm.nih.gov/pubmed/33432929 http://dx.doi.org/10.7554/eLife.57646 |
Ejemplares similares
-
Estimation of the in vivo neutralization potency of eCD4Ig and conditions for AAV-mediated production for SHIV long-term remission
por: Goyal, Ashish, et al.
Publicado: (2022) -
To rebound or not to rebound
por: Stahl, Bethany A, et al.
Publicado: (2017) -
Assessing the impact of autologous neutralizing antibodies on viral rebound in postnatally SHIV-infected ART-treated infant rhesus macaques
por: Mainou, Ellie, et al.
Publicado: (2023) -
Antibody and TLR7 Agonist Delay Viral Rebound in SHIV-Infected Monkeys
por: Borducchi, Erica N., et al.
Publicado: (2018) -
CTL-mediated immunotherapy can suppress SHIV rebound in ART-free macaques
por: Fan, Jin, et al.
Publicado: (2019)